Efficacy Study to Treat Subjects With Severe Hypertriglyceridemia
This trial is active, not recruiting.
|Sponsor||Trygg Pharma, Inc.|
|Start date||October 2010|
|End date||July 2012|
|Trial size||240 participants|
|Trial identifier||NCT01229566, TRGG-963-002|
The primary objective is to determine the efficacy of AKR963 compared to placebo and active comparator in lowering fasting triglyceride levels in patients with very high fasting triglyceride levels ≥ 500 and ≤ 1500 mg/dL.
|Endpoint classification||safety/efficacy study|
|Intervention model||parallel assignment|
|Masking||double blind (subject, caregiver, investigator, outcomes assessor)|
Difference between AKR963 and Control [placebo or active control] treatment groups in triglyceride lowering effect [ Time Frame: 12 weeks ]
time frame: 12 weeks
Male or female participants from 18 years up to 79 years old.
Inclusion Criteria: - Men and women, ages 18-79 - Fasting triglyceride ≥500 mg/dL and ≤1500 mg/dL - Provide written informed consent and authorization for protected health information disclosure Exclusion Criteria: - Women who are pregnant or lactating, or planning to become pregnant - Use of non-statin lipid-altering drugs which cannot be stopped or other supplements with potential lipid-altering effects - History of pancreatitis - History of bariatric surgery or currently on weight loss drugs or in weight loss programs - Treatment with any agent that may affect lipid levels or hepatic function - Consumption of more than 3 alcoholic beverages per day - History of cancer within last 2 years - Participation in another clinical trial involving an investigational agent in the last 30 days - Other parameters will be assessed at the study center to ensure eligibility for this study
|Official title||A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase III Study to Assess Efficacy and Safety of AKR-963 Therapy in Subjects With Severe Hypertriglyceridemia|
|Principal investigator||Kevin C Maki, PhD|
|Description||Increases in triglyceride concentrations have been correlated with increased risk for pancreatitis as well as for coronary heart disease (Ginsberg 2001, 2002). The incidence rates for major coronary events in the Munster Heart Study increased from 4.4% among Subjects with baseline TG concentrations under 200 mg/dL to 9.3% among Subjects with TG concentrations in the 200-399 mg/dL range, and up to 13.2% in Subjects with TG levels ranging from 400-799 mg/dL (Assmann 1996).|
Call for more information